BMJ：用药减重越快，停药反弹越猛！牛津团队发现，停用减重药物后的体重和心血管获益，会在1-2年内反弹回用药前

Core Insights - Obesity is a chronic and relapsing disease affecting nearly 2 billion adults globally, increasing the risk of other chronic diseases and premature death [1][9] - The emergence of GLP-1 receptor agonists and GLP-1/GIP dual agonists is seen as a transformative approach to obesity treatment, offering significant weight loss and cardiovascular protection [1][9] - A recent systematic review and meta-analysis published in the BMJ highlights the common issue of weight regain after cessation of these medications, emphasizing the need for understanding this rebound for long-term management [9][14] Study Overview - The analysis included 37 studies with 9,341 participants and an average follow-up of 32 weeks, focusing on weight management medications compared to non-pharmacological interventions or placebos [9][10] - Among the studies, 35 were randomized controlled trials, but only 28 had control groups during both intervention and follow-up periods [10] Weight Loss and Rebound - The average weight loss during treatment across all medication groups was 8.3 kg, compared to 3.2 kg in control groups [11] - GLP-1 receptor agonists achieved an average weight loss of 10.1 kg, while newer agents like semaglutide and tirzepatide reached 14.7 kg [11] - Post-medication, the average weight regain rate was 0.4 kg/month, with a return to baseline weight expected in 1.7 years [11][14] Cardiovascular and Metabolic Indicators - During treatment, HbA1c decreased by 0.9 mmol/mol, with a monthly increase of 0.05 mmol/mol post-treatment [13] - Other indicators such as fasting blood glucose, systolic blood pressure, and cholesterol levels also showed significant reductions during treatment, but began to rise again after cessation [13] Comparison with Behavioral Interventions - Behavioral interventions resulted in an average weight loss of 5.1 kg, with a slower rebound rate of 0.1 kg/month, taking approximately 3.9 years to return to baseline [7][14] - Sensitivity analyses indicated that the rebound rate for medication groups was consistently faster than for behavioral interventions, regardless of initial weight loss [7][14] Conclusion and Future Directions - The findings suggest that while weight loss medications are effective, their benefits diminish after discontinuation, necessitating long-term management strategies [14] - The commentary accompanying the study stresses that GLP-1 receptor agonists should not be viewed as a "magic bullet" for obesity, highlighting the importance of a healthy diet and lifestyle as foundational elements of obesity management [14]